Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

E-resources

Peer reviewed Open access

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

Sandborn, William J; Feagan, Brian G; D’Haens, Geert; Wolf, Douglas C; Jovanovic, Igor; Hanauer, Stephen B; Ghosh, Subrata; Petersen, AnnKatrin; Hua, Steven Y; Lee, Ji Hwan; Charles, Lorna; Chitkara, Denesh; Usiskin, Keith; Colombel, Jean-Frederic; Laine, Loren; Danese, Silvio

New England journal of medicine/The New England journal of medicine, 09/2021, Volume: 385, Issue: 14

Journal Article

In a phase 3 trial, patients with moderately to severely active ulcerative colitis were randomly assigned to receive placebo or ozanimod, a selective sphingosine-1-phosphate receptor modulator. Clinical remission was significantly greater with ozanimod during the induction and maintenance periods. The incidence of infection was higher with ozanimod than with placebo during maintenance.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme